Estimating the clinical cost of drug development for orphan versus non-orphan drugs

Kavisha Jayasundara, Aidan Hollis, Murray Krahn, Muhammad Mamdani, Jeffrey S Hoch, Paul Grootendorst

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse. Methods: Using publicly available data, we estimated the differences in trial characteristics and clinical development costs with 100 orphan and 100 non-orphan drugs. Results: We found that the out-of-pocket clinical costs per approved orphan drug to be $166 million and $291 million (2013 USD) per non-orphan drug. The capitalized clinical costs per approved orphan drug and non-orphan drug were estimated to be $291 million and $412 million respectively. When focusing on new molecular entities only, we found that the capitalized clinical cost per approved orphan drug was half that of a non-orphan drug. Conclusions: More discussion is needed to better align on which cost components should be included in research and development costs for pharmaceuticals.

Original languageEnglish (US)
Article number12
JournalOrphanet Journal of Rare Diseases
Volume14
Issue number1
DOIs
StatePublished - Jan 10 2019

Fingerprint

Orphan Drug Production
Drug Costs
Costs and Cost Analysis
Pharmaceutical Preparations
Orphaned Children
Health Expenditures
Administrative Personnel
Clinical Trials
Research

Keywords

  • Cost of drug development
  • Orphan drugs
  • Rare diseases

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Estimating the clinical cost of drug development for orphan versus non-orphan drugs. / Jayasundara, Kavisha; Hollis, Aidan; Krahn, Murray; Mamdani, Muhammad; Hoch, Jeffrey S; Grootendorst, Paul.

In: Orphanet Journal of Rare Diseases, Vol. 14, No. 1, 12, 10.01.2019.

Research output: Contribution to journalArticle

Jayasundara, Kavisha ; Hollis, Aidan ; Krahn, Murray ; Mamdani, Muhammad ; Hoch, Jeffrey S ; Grootendorst, Paul. / Estimating the clinical cost of drug development for orphan versus non-orphan drugs. In: Orphanet Journal of Rare Diseases. 2019 ; Vol. 14, No. 1.
@article{2566cf353cb84aa08dfb90575c103fe9,
title = "Estimating the clinical cost of drug development for orphan versus non-orphan drugs",
abstract = "Background: High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse. Methods: Using publicly available data, we estimated the differences in trial characteristics and clinical development costs with 100 orphan and 100 non-orphan drugs. Results: We found that the out-of-pocket clinical costs per approved orphan drug to be $166 million and $291 million (2013 USD) per non-orphan drug. The capitalized clinical costs per approved orphan drug and non-orphan drug were estimated to be $291 million and $412 million respectively. When focusing on new molecular entities only, we found that the capitalized clinical cost per approved orphan drug was half that of a non-orphan drug. Conclusions: More discussion is needed to better align on which cost components should be included in research and development costs for pharmaceuticals.",
keywords = "Cost of drug development, Orphan drugs, Rare diseases",
author = "Kavisha Jayasundara and Aidan Hollis and Murray Krahn and Muhammad Mamdani and Hoch, {Jeffrey S} and Paul Grootendorst",
year = "2019",
month = "1",
day = "10",
doi = "10.1186/s13023-018-0990-4",
language = "English (US)",
volume = "14",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Estimating the clinical cost of drug development for orphan versus non-orphan drugs

AU - Jayasundara, Kavisha

AU - Hollis, Aidan

AU - Krahn, Murray

AU - Mamdani, Muhammad

AU - Hoch, Jeffrey S

AU - Grootendorst, Paul

PY - 2019/1/10

Y1 - 2019/1/10

N2 - Background: High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse. Methods: Using publicly available data, we estimated the differences in trial characteristics and clinical development costs with 100 orphan and 100 non-orphan drugs. Results: We found that the out-of-pocket clinical costs per approved orphan drug to be $166 million and $291 million (2013 USD) per non-orphan drug. The capitalized clinical costs per approved orphan drug and non-orphan drug were estimated to be $291 million and $412 million respectively. When focusing on new molecular entities only, we found that the capitalized clinical cost per approved orphan drug was half that of a non-orphan drug. Conclusions: More discussion is needed to better align on which cost components should be included in research and development costs for pharmaceuticals.

AB - Background: High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse. Methods: Using publicly available data, we estimated the differences in trial characteristics and clinical development costs with 100 orphan and 100 non-orphan drugs. Results: We found that the out-of-pocket clinical costs per approved orphan drug to be $166 million and $291 million (2013 USD) per non-orphan drug. The capitalized clinical costs per approved orphan drug and non-orphan drug were estimated to be $291 million and $412 million respectively. When focusing on new molecular entities only, we found that the capitalized clinical cost per approved orphan drug was half that of a non-orphan drug. Conclusions: More discussion is needed to better align on which cost components should be included in research and development costs for pharmaceuticals.

KW - Cost of drug development

KW - Orphan drugs

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=85059828850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059828850&partnerID=8YFLogxK

U2 - 10.1186/s13023-018-0990-4

DO - 10.1186/s13023-018-0990-4

M3 - Article

C2 - 30630499

AN - SCOPUS:85059828850

VL - 14

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 12

ER -